Abstract
Malignant melanoma is one of the most highly invasive and metastatic tumors. Melanoma is an increasingly common malignancy as well, and its mortality rates have been rapidly increasing above those of any other cancer in recent years. Surgical resection and systemic chemotherapy are the main therapeutic strategies for the treatment of malignant melanoma. However, these approaches are insufficiently effective and may be associated with significant adverse effects. Angiogenesis, a process by which new vascular networks are formed from pre-existing capillaries, is required for tumors to grow, invade and metastasize. Tumor vessels are genetically stable, and less likely to accumulate mutations that allow them to develop drug resistance in a rapid manner. Therefore, targeting vasculatures that support tumor growth, rather than cancer cells, is considered the most promising approach to malignant melanoma therapy. Now, novel anti-angiogenic agents with tolerable side effects is actually desired for the treatment of patients with malignant melanoma. In this paper, we review the current understanding of anti-angiogenic therapy for malignant melanoma, especially focusing on pigment epithelium-derived factor (PEDF), which was recently identified as the most potent endogenous inhibitor of angiogenesis in the mammalian eye. We also discuss here the involvement of a receptor for advanced glycation end products (RAGE) in angiogenesis, melanoma growth and metastasis, and the therapeutic implications of the blockers of RAGE in this devastating disorder.
Keywords: matrix metalloproteinase, VEGF expression, basic fibroblast growth factor, extracellular matrix, Thrombospondin-1, Pigment Epithelium-Derived Factor
Mini-Reviews in Medicinal Chemistry
Title: Angiogenesis and Metastasis Inhibitors for the Treatment of Malignant Melanoma
Volume: 7 Issue: 6
Author(s): Riichiro Abe, Yasuyuki Fujita and Sho-ichi Yamagishi
Affiliation:
Keywords: matrix metalloproteinase, VEGF expression, basic fibroblast growth factor, extracellular matrix, Thrombospondin-1, Pigment Epithelium-Derived Factor
Abstract: Malignant melanoma is one of the most highly invasive and metastatic tumors. Melanoma is an increasingly common malignancy as well, and its mortality rates have been rapidly increasing above those of any other cancer in recent years. Surgical resection and systemic chemotherapy are the main therapeutic strategies for the treatment of malignant melanoma. However, these approaches are insufficiently effective and may be associated with significant adverse effects. Angiogenesis, a process by which new vascular networks are formed from pre-existing capillaries, is required for tumors to grow, invade and metastasize. Tumor vessels are genetically stable, and less likely to accumulate mutations that allow them to develop drug resistance in a rapid manner. Therefore, targeting vasculatures that support tumor growth, rather than cancer cells, is considered the most promising approach to malignant melanoma therapy. Now, novel anti-angiogenic agents with tolerable side effects is actually desired for the treatment of patients with malignant melanoma. In this paper, we review the current understanding of anti-angiogenic therapy for malignant melanoma, especially focusing on pigment epithelium-derived factor (PEDF), which was recently identified as the most potent endogenous inhibitor of angiogenesis in the mammalian eye. We also discuss here the involvement of a receptor for advanced glycation end products (RAGE) in angiogenesis, melanoma growth and metastasis, and the therapeutic implications of the blockers of RAGE in this devastating disorder.
Export Options
About this article
Cite this article as:
Riichiro Abe , Yasuyuki Fujita and Sho-ichi Yamagishi , Angiogenesis and Metastasis Inhibitors for the Treatment of Malignant Melanoma, Mini-Reviews in Medicinal Chemistry 2007; 7 (6) . https://dx.doi.org/10.2174/138955707780859440
DOI https://dx.doi.org/10.2174/138955707780859440 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [ Immune Receptors for Glycoconjugates Guest Editor: Dapeng Zhou ]
Current Protein & Peptide Science Archaeosome Immunostimulatory Vaccine Delivery System
Current Drug Delivery New Developments in Anti-Angiogenic Therapy of Cancer, Review and Update
Anti-Cancer Agents in Medicinal Chemistry Molecular Pharmacology and Pharmacogenomics of Artemisinin and its Derivatives in Cancer Cells
Current Drug Targets PEGylated Peptide-Based Imaging Agents for Targeted Molecular Imaging
Current Protein & Peptide Science Dehydroepiandrosterone, Dehydroepiandrosterone Sulfate and Related Steroids: Their Role in Inflammatory, Allergic and Immunological Disorders
Current Drug Targets - Inflammation & Allergy Indole Compounds Against Breast Cancer: Recent Developments
Current Drug Targets The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection
Current Medicinal Chemistry Rho GTPase Activating Proteins in Cancer Phenotypes
Current Protein & Peptide Science Protective Effects of Chronic Green Tea Consumption on Age-related Neurodegeneration
Current Pharmaceutical Design The Complex Biology of FOXO
Current Drug Targets Molecular Mechanism of Inhibition of Polysialyltransferase Domain (PSTD) by Heparin
Current Topics in Medicinal Chemistry Synergistic Interaction of Telomerase-Specific Oncolytic Virotherapy and Chemotherapeutic Agents for Human Cancer
Current Pharmaceutical Biotechnology Natural Products Containing Olefinic Bond: Important Substrates for Semi-synthetic Modification Towards Value Addition
Current Organic Chemistry Pharmacogenetics of Phase I and Phase II Drug Metabolism
Current Pharmaceutical Design <i>In vivo</i> Anticancer Potential of Hydroxamic Acid Derivatives
Current Topics in Medicinal Chemistry Tubulin-Targeting Agents in Hybrid Drugs
Current Medicinal Chemistry Multifunctional Radiolabeled Nanoparticles for Targeted Therapy
Current Medicinal Chemistry Melatonin and Hypothalamic-Pituitary-Gonadal Axis
Current Medicinal Chemistry Mechanisms of Drug Resistance in Cancer Chemotherapy: Coordinated Role and Regulation of Efflux Transporters and Metabolizing Enzymes
Current Pharmaceutical Design